Literature DB >> 11438135

Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells.

A Lalvani1, A A Pathan, H Durkan, K A Wilkinson, A Whelan, J J Deeks, W H Reece, M Latif, G Pasvol, A V Hill.   

Abstract

BACKGROUND: Identification of individuals latently infected with Mycobacterium tuberculosis is an important part of tuberculosis control. The current method, the tuberculin skin test (TST), has poor specificity because of the antigenic cross-reactivity of purified protein derivative (PPD) with M bovis BCG vaccine and environmental mycobacteria. ESAT-6 is a secreted antigen that is highly specific for M tuberculosis complex, but is absent from M bovis BCG. With an enzyme-linked immunospot (ELISPOT) assay for interferon gamma, we have identified ESAT-6-specific T cells as an accurate marker of M tuberculosis infection.
METHODS: We did a prospective, masked study of 50 healthy contacts, with varying but well defined degrees of exposure to M tuberculosis, who attended an urban contact-tracing clinic. We assessed and compared the efficacy of our assay and TST for detection of symptomless infected individuals by correlation of test results with the degree of exposure to an infectious index case.
FINDINGS: The ESAT-6 ELISPOT assay results had a strong positive relation with increasing intensity of exposure (odds ratio=9.0 per unit increase in level of exposure [95% CI 2.6--31.6], p=0.001), whereas TST results had a weaker relation with exposure (1.9 [1.0--3.5], p=0.05). By contrast, ELISPOT results were not correlated with BCG vaccination status (p=0.7), whereas TST results were significantly more likely to be positive in BCG-vaccinated contacts (12.1 [1.3--115.7], p=0.03).
INTERPRETATION: This new antigen-specific T cell-based assay could allow more accurate identification of symptom-free individuals recently exposed to M tuberculosis, and thereby help to improve tuberculosis control.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438135     DOI: 10.1016/S0140-6736(00)05115-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  98 in total

1.  ESAT-6 and CFP-10: what is the diagnosis?

Authors:  Nico C Gey van Pittius; Robin M Warren; Paul D van Helden
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 2.  What is Good's syndrome? Immunological abnormalities in patients with thymoma.

Authors:  P Kelleher; S A Misbah
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

Review 3.  Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.

Authors:  Chrysanthi L Skevaki; Dimitrios A Kafetzis
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment.

Authors:  Sonia Mínguez; Irene Latorre; Lourdes Mateo; Alicia Lacoma; Jéssica Diaz; Alejandro Olivé; Jose Domínguez
Journal:  Clin Rheumatol       Date:  2012-01-21       Impact factor: 2.980

5.  An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection.

Authors:  Luigi Codecasa; Paola Mantegani; Laura Galli; Adriano Lazzarin; Paolo Scarpellini; Claudio Fortis
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

6.  Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice.

Authors:  T Meier; H-P Eulenbruch; P Wrighton-Smith; G Enders; T Regnath
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 7.  Testing for latent tuberculosis.

Authors:  Asad Ayub; Steven H Yale; Kurt D Reed; Rana M Nasser; Steven R Gilbert
Journal:  Clin Med Res       Date:  2004-08

8.  Repeated tuberculin testing does not induce false positive ELISPOT results.

Authors:  L Richeldi; K Ewer; M Losi; P Roversi; L M Fabbri; A Lalvani
Journal:  Thorax       Date:  2006-02       Impact factor: 9.139

9.  The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon.

Authors:  Abebech Demissie; Liya Wassie; Markos Abebe; Abraham Aseffa; Graham Rook; Alimuddin Zumla; Peter Andersen; T Mark Doherty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

10.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.